X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Roche obtains global development, manufacturing, and commercialization rights to RO7117997, an IND-ready ENT1 inhibitor discovered using the PsychoGenics’ AI-enabled phenotypic screening platforms.
Lead Product(s): RO7117997
Therapeutic Area: Sleep Product Name: RO7117997
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 01, 2023
Details:
The funding will be used develop and apply machine learning (ML) tools to explore new areas of chemistry, with the ultimate aim of identifying treatments that target novel or multiple aspects of complex neuropsychiatric disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: SBIR Grant
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 05, 2023
Details:
PsychoGenics will evaluate the anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which restore the physiological hyperpolarizing and inhibitory GABAergic transmission in a preclinical model of Dravet syndrome.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: IAMA Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 12, 2023
Details:
The agreement, allowed Karuna to leverage Psychogenics proprietary screening platforms, which utilize computer vision and machine learning to identify and evaluate new drug candidates including KAR-501 to further its pipeline of differentiated neuropsychiatric drugs.
Lead Product(s): KAR-501
Therapeutic Area: Neurology Product Name: KAR-501
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karuna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
